India's GLP-1 race intensifies with the launch of Ozempic ...

Novo Nordisk, a Danish pharmaceutical company, has launched its weight-loss drug Wegovy in India. The drug, which contains semaglutide, works by regulating appetite and food intake, and is now the ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...

In November, Mounjaro clocked Rs 108 crore in sales, making it the number 1 brand in the IPM, reflecting sustained momentum ...

By Rishika Sadam HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

HYDERABAD (Reuters) -Sales of Danish drugmaker Novo Nordisk's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on ...

A steep price drop for Wegovy and strong uptake of Mounjaro pushed GLP-1 weight-loss drugs to new highs in November. The ...

Novo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 ...

HYDERABAD (Reuters) - Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly in the populous nation, two ...

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly ...

Global blockbuster fat-busting injection Mounjaro became India's top-selling medicine brand within months of its launch ...